FDA's 2026 Supplement Overhaul: The Biggest Regulatory Shift in Decades

By HiMiyer.com — March 23, 2026

Background: A Law Frozen in 1994

The U.S. dietary supplement industry has operated under the Dietary Supplement Health and Education Act (DSHEA) since 1994. That law defined what counts as a dietary supplement and carved out a regulatory space distinct from both food and pharmaceuticals. Under DSHEA, manufacturers do not need premarket FDA approval for safety or efficacy — they are responsible for ensuring their own products are safe before going to market.

That framework has remained largely intact for 32 years. In 2026, the FDA is moving on multiple fronts to modernize it — and the pace of change is faster than the industry expected.

The March 27 Public Meeting

On March 3, 2026, the FDA announced a hybrid public meeting titled "Exploring the Scope of Dietary Supplement Ingredients," scheduled for March 27, 2026 (9 a.m.–3 p.m. ET) at the agency's College Park, Maryland campus and available virtually.

The meeting is being convened by the FDA's Office of Dietary Supplement Programs (ODSP) and will tackle three core questions:

• What does the phrase "dietary substance for use by man to supplement the diet by increasing the total dietary intake" actually mean under DSHEA — a definition experts describe as a broad catch-all?
• Do new production methods — specifically precision fermentation, cell culture technology, and recombinant processes — qualify ingredients produced by those methods as legal dietary ingredients?
• How should specific ingredient categories, including proteins, enzymes, and microbials, be treated under the existing framework?

Public comments are open through April 27, 2026, via docket number FDA-2026-N-2047 at regulations.gov. The FDA has stated it will use input from the meeting and comment period to determine its next regulatory steps.

The meeting was partly driven by industry pressure. In early January, the Natural Products Association (NPA) had formally petitioned the FDA to hold exactly this kind of stakeholder session. At the time, the FDA declined. The agency's reversal six weeks later signals that the policy agenda has shifted significantly.

Label Disclaimer Changes Under Review

Separately, the FDA is considering a rule change that would reduce how prominently the standard DSHEA disclaimer must appear on supplement packaging. Under current law, any supplement that makes a structure/function claim — for example, "supports immune health" — must carry a conspicuous notice on every panel stating the claim has not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease.

The proposed revision would require that disclaimer on only one panel of a product's packaging, reducing label clutter and compliance costs for manufacturers. The FDA framed the change as a streamlining measure.

Critics are not convinced. Pieter Cohen, MD, an associate professor of medicine at Harvard Medical School, told NBC News that shifting disclaimers to less prominent placement could lead to consumers overlooking them entirely — particularly vulnerable groups such as older adults, pregnant individuals, or those managing chronic conditions with multiple medications.

Roughly three-quarters of Americans report regular use of at least one supplement, and an estimated 80,000 to 100,000 supplement products are currently on the market. Public health advocates argue that at that scale, even small reductions in label clarity carry meaningful risk.

GRAS Reform: Self-Certification Era Ending

A third pillar of the 2026 regulatory shift involves the "Generally Recognized as Safe" (GRAS) pathway. Currently, ingredient manufacturers can self-determine GRAS status without notifying the FDA — a practice that has allowed thousands of substances to enter the food and supplement supply without agency review.

Under pressure from HHS Secretary Robert F. Kennedy Jr. — who raised the issue directly during his Senate confirmation hearings — the FDA is moving toward a proposed rule that would require mandatory submission of GRAS notices for all new substances. The proposed rule was initially expected in October 2025; a government shutdown delayed it. Industry observers now expect it to arrive in 2026.

If finalized, the rule would represent a foundational change in how ingredients reach the market. Ingredient onboarding timelines would lengthen, and the evidence burden for demonstrating safety would increase substantially.

Industry Reaction

Supplement industry stakeholders have responded with a mix of cautious optimism and concern. Some welcome long-overdue modernization, particularly around the drug preclusion clause — a DSHEA provision that blocks ingredients previously studied as pharmaceuticals from being sold as supplements, a rule that has created regulatory uncertainty for a growing category of novel bioactives.

Others worry that tighter GRAS rules and higher NDI (New Dietary Ingredient) submission standards will stifle innovation, especially for growth-stage companies with fewer resources to navigate a more demanding compliance environment. The Natural Products Association has launched a nationwide campaign to preserve DSHEA's federal framework and push back against a wave of conflicting state-level supplement legislation.

Legal experts tracking the changes note that 2026 could be the most consequential year for dietary supplement regulation since Good Manufacturing Practices (GMPs) were introduced — a threshold that has been cited repeatedly across industry coverage in recent weeks.

What This Means for Consumers

For supplement buyers, the near-term practical impact is limited — no rules have been finalized, and any changes that emerge from the March 27 meeting will go through a formal notice-and-comment rulemaking process before taking effect.

The longer-term implications are more significant. A more structured regulatory environment could increase confidence in product safety and ingredient transparency. It may also narrow the range of available ingredients if borderline substances — especially those produced via precision fermentation or cell culture — are ruled outside the DSHEA definition.

Consumers with specific health concerns are encouraged to consult a healthcare provider before starting any supplement regimen, regardless of how regulatory frameworks evolve.

Sources

• FDA — Announcing Public Meeting on Dietary Supplement Innovation (March 3, 2026)
• FDA — Public Meeting: Exploring the Scope of Dietary Supplement Ingredients (March 27, 2026)
• NutraIngredients — Could 2026 Be the Biggest Year for Dietary Supplements Since GMPs? (March 5, 2026)
• Pharmacy Times — FDA May Relax Dietary Supplement Warning Label Rules (January 2, 2026)
• Intermountain Nutrition — FDA Human Foods Program 2026 Analysis (March 2026)
• SupplySide SJ — DSHEA Definition Subject of FDA Meeting (March 2026)
• SupplySide SJ — FDA GRAS Reform Timeline Accelerates (October 2025)
• Food Safety Magazine — FDA to Hold Public Meeting on Scope of Dietary Supplement Ingredients